Entering text into the input field will update the search result below

Bristol's up to $3B deal with Eisai puts antibody drug conjugates in the spotlight

Molecular model of immunoglobulin
Dr_Microbe/iStock via Getty Images

  • Today's up to $3B development and commercialization deal from Bristol-Myers Squibb (NYSE:BMY) for Eisai's (OTCPK:ESALY) for MORAb-202 is putting antibody drug conjugates ("ADCs"), which some feel is the future of cancer therapeutics, into the spotlight.
  • The ones

Recommended For You

Related Stocks

SymbolLast Price% Chg
ADCT--
ADC Therapeutics SA
GILD--
Gilead Sciences, Inc.
DSKYF--
Daiichi Sankyo Company, Limited
AZN--
AstraZeneca PLC
ABBV--
AbbVie Inc.